

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT  
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 3, 2026

**HARROW, INC.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction  
of incorporation)

**001-35814**  
(Commission  
File Number)

**45-0567010**  
(IRS Employer  
Identification No.)

**1A Burton Hills Blvd., Suite 200**  
**Nashville, Tennessee**  
(Address of principal executive offices)

**37215**  
(Zip Code)

Registrant's telephone number, including area code: **(615) 733-4730**

**Not Applicable**

(Former Name or Former Address, if Changed Since Last Report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, \$0.001 par value per share	HROW	The Nasdaq Stock Market LLC

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Act of 1934: Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 7.01. Regulation FD Disclosure.**

Attached as Exhibit 99.1 to this Current Report on Form 8-K is a corporate presentation of Harrow, Inc. (the "Company"), dated June 2026, which may be used from time to time by the Company's management at investor conferences and in meetings with investors, analysts and other interested parties.

The information furnished under Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be "filed" for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such filing.

**Item 9.01. Financial Statements and Exhibits.**

**(d) Exhibits**

99.1 [Harrow Corporate Presentation dated June 2026](#)

104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**HARROW, INC.**

Dated: June 3, 2026

By: /s/ Andrew R. Boll  
Name: Andrew R. Boll  
Title: President & Chief Financial Officer

---



# William Blair 46th Annual Growth Stock Conference

June 2026



**HARROW**<sup>®</sup>  
Your patients. Our purpose.

# Safe Harbor

This presentation contains "forward-looking statements" as defined in the U.S. Private Securities Litigation Reform Act of 1995. You are cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Harrow, Inc. (the "Company" or "Harrow"). Some of these risks and uncertainties include, but are not limited to: liquidity or results of operations; our ability to successfully implement our business plan, develop and commercialize our products, product candidates and proprietary formulations in a timely manner or at all, identify and acquire additional products, manage our pharmacy operations, service our debt, obtain financing necessary to operate our business, recruit and retain qualified personnel, manage any growth we may experience and successfully realize the benefits of our previous acquisitions and any other acquisitions and collaborative arrangements we may pursue; competition from pharmaceutical companies, outsourcing facilities and pharmacies; general economic and business conditions, including inflation and supply chain challenges; regulatory and legal risks and uncertainties related to our pharmacy operations and the pharmacy and pharmaceutical business in general, including the ongoing communications with the U.S. Food and Drug Administration related to compliance and quality plans at our resourcing facility in New Jersey; and physician interest in and market acceptance of our current and any future formulations and compounding pharmacies generally. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission, including its Annual Reports on Form 10-K and its Quarterly Reports on Form 10-Q filed with the SEC. Such documents may be read free of charge on the SEC's web site at [www.sec.gov](http://www.sec.gov). All forward-looking statements are qualified in their entirety by this cautionary statement. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Harrow expressly disclaims any intent or obligation to update these forward-looking statements except as required by law. The Company's compounded formulations are not FDA approved. All trademarks, service marks and trade names included in this presentation are the property of their respective owners. This presentation refers to non-GAAP financial measures, specifically adjusted EBITDA. A reconciliation and/or further description of any non-GAAP measures with the most directly comparable GAAP measures are included in the Company's Letters to Stockholders, available on its website. All content included in this presentation is intended for investors and the investment community and is not intended as marketing material or for use by healthcare professionals and their patients.

# Harrow. We are Ophthalmic Pharma.

Founder-led Diversified Provider of Ophthalmic Disease Management Solutions in North America

Largest U.S. portfolio of prescription ophthalmic products broadly covering the ophthalmic anatomy

Key revenue drivers are best-in-class products in large underpenetrated markets; near-term launches support "key vendor status" in surgical and retina franchises

**Delivery Types:**                   Injectable | Topical | Device

**Product Categories:**           Buy & Bill | Branded | Generic  
Over-the-Counter | Compounded

**Disease Origins:**               Anterior | Posterior | Ocular Surface

**Payer Types:**                   Commercial | Government | Cash

vēvye® | Dry Eye Disease | **Launched 2024**

IHEEZO | Ocular Anesthesia | **Launched 2023**

Triesence | PF Corticosteroid (Injection) | **Re-Launched 2024**

Byooviz® | Anti-VEGF Biosimilar | **Launch: July 2026**

OPUVIZ™ | Anti-VEGF Biosimilar | **Est. Launch: 2027**

G-MELT™  
Drug Candidate | Procedural Sedation | **Est. Launch: 2028**

Advancing the Standard of Eye Care | Accessibility and Affordability | Enhancing Patient Compliance | Improving Clinical Outcomes

# Harrow's Ophthalmic Pharmaceutical Brands

**BYQLOVI™**  
(cibetazolol propionate ophthalmic suspension) 0.05%

**IHEEZO**  
(chloropropane HCl ophthalmic gel) 3%

**Flarex®**  
(flurametholone acetate ophthalmic suspension) 0.1%

**Maxidex®**  
(dexamethasone ophthalmic suspension) 0.1%

**Maxitrol®**  
(neomycin and polymyxin B sulfates and dexamethasone ophthalmic suspension)

**Natacyn®**  
(natamycin ophthalmic suspension) 5%

**ZERVIAE™**  
cetirizine ophthalmic solution, 0.24%  
FORMULATED WITH HYDRELLA

**vēvyē®**  
(cyclosporine ophthalmic solution) 0.1%

**TobraDex-ST**  
(tobramycin/dexamethasone ophthalmic suspension) 0.3%/0.05%  
FORMULATED WITH XanGen™

**Verkazia®**  
cyclosporine ophthalmic emulsion 0.1%

**Vigamox®**  
(moxifloxacin HCl ophthalmic solution) 0.5% as base

**FRESHKOTE®**  
Preservative Free  
LUBRICANT EYE DROPS

**Moxeza®**  
(moxifloxacin HCl ophthalmic solution) 0.5% as base

**ILEVRO®**  
(nepafenac ophthalmic suspension) 0.3%


**IOPIDINE®**  
(apraclonidine hydrochloride ophthalmic solution)

**Nevanac®**  
(nepafenac ophthalmic suspension) 0.1%

Ocular Surface

Anterior Segment

Posterior Segment



**Triésence**  
(triamcinolone acetonide injectable suspension) 40 mg/mL

**Byooviz™**  
(ranibizumab-nuna) 0.05mL injection

**Opuviz™**  
aflibercept-yszy



**imprimis Rx®**  
A HARROW COMPANY

# Financials & Outlook

# Key Financial Metrics & 2026 Outlook

Five years of consistent revenue and EBITDA expansion

## FIVE-YEAR TRACK RECORD



## 2026 Outlook

Q2 '26 Revenue Range

**\$71M – \$81M**

Midpoint ~\$76M

FY '26 Revenue

**\$350M – \$365M**

Midpoint ~\$357.5M

FY '26 EBITDA

**\$80M – \$100M**

Midpoint ~\$90M

<sup>(1)</sup> Adjusted EBITDA is defined as net income (loss), excluding the effects of stock-based compensation and expenses, impairment of intangible assets, interest, taxes, depreciation, amortization, investment (income) loss, net, and, if any and when specified, other non-recurring income or expense items. Management believes that the most directly comparable GAAP financial measure to Adjusted EBITDA is net income (loss). Adjusted EBITDA has limitations and should not be considered as an alternative to gross profit or net income (loss) as a measure of operating performance or to net cash provided by (used in) operating, investing, or financing activities as a measure of ability to meet cash needs.

# Dry Eye Disease

VEVYE



# Dry Eye Disease Differentiation

## Dry Eye Disease Dilemma (or opportunity):

- Large market (30+ million Americans); <10% on therapy
- Therapeutic persistence (i.e., *refilling*) is low due to burning, stinging, or a lack of an anti-inflammatory active ingredient



\*Preclinical ex vivo corneal penetration study data

**~22x**

First and only water-free cyclosporine for the signs and symptoms of DED – delivers more cyclosporine to the cornea vs. Restasis\*

### **Rapid Onset**

Fastest-working immunomodulator for dry eye

### **Durable Effect**

Clinically meaningful, statistically significant improvement in total fluorescent staining by Day 15 — sustained to 56 weeks

### **Well-Tolerated**

99.8% of patients experience no or mild instillation pain

### **IP Protection**

Orange Book-listed patents with expiry in 2039

# Durability of Revenue

## New Rx + Refills = Compounding

~9x annual refill rate for covered patients



<sup>2&3</sup>: IQVIA Xponent and internal datasets, month of March 2026

## Q1 '26 Highlights

~25%

NRx Growth  
Q1 '26 vs Q4 '25

~11%

TRx Growth  
Q1 '26 vs Q4 '25

+12%

Prescriber Growth  
Q1 '26 vs Q4 '25

14%

Market Share  
As of end of March '26

- ✓ Surpassed XIIDRA on monthly TRx market share basis<sup>2</sup>
- ✓ Only branded product to materially grow in Q1 '2026<sup>3</sup>
- ✓ Improved Coverage; preferred status with largest U.S. commercial PBM
- ✓ Expanded Sales Force; sales force doubled to 100 territories expanding frequency and reach expected to drive NRx & TRx growth

# Ocular Anesthesia

IHEEZO



Sterile, single-patient-use, physician-administered, ophthalmic gel preparation for ocular surface anesthesia, approved by the FDA in September 2022

- **First-in-class:** only branded ocular anesthetic approved in the U.S. in nearly 14 years
- **Large TAM:** >14M annual U.S. ocular procedures require surface anesthesia
- **Reimbursement unlocked:** permanent J-Code (J2403) in the in-office setting
- **IP runway:** two Orange Book patents, latest expiring 2039
- **Clinical advantage:** rapid onset, lower pain vs. tetracaine, no supplemental dosing required, inactive ingredient hydroxyethyl cellulose, typically used in eye lubricants/tears

## IHEEZO clinical studies demonstrated:



IHEEZO worked rapidly



IHEEZO had lower pain scores vs tetracaine



Sufficient anesthesia to perform the surgical procedure



No patient required supplemental dosing

# IHEEZO's Total Addressable Market

**IHEEZO**  
(chloroprocaine HCl ophthalmic gel) 3

**~14M+** Estimated Annual U.S. In-Office Procedures | *Standard of Care = Ocular Surface Anesthesia*

**~10M+**

✓ IHEEZO

Intravitreal Injections

CPT: 67028

**~1.5M+**

✓ IHEEZO

Laser Procedures

CPT: 65855 / 66761 / 67210

**~1M+**

✓ IHEEZO

Gonioscopy (Procedural)

CPT: 92020

**~700K**

✓ IHEEZO

Foreign Body Removal

CPT: 65222 / 65205

## Additional In-Office Procedures

**~330K**

✓ IHEEZO

Corneal Procedures

CPT: 65435 / 0402T

**~200K**

✓ IHEEZO

Glaucoma Implant

CPT: 66183-66185

**~300K**

✓ IHEEZO

Punctal Occlusion

CPT: 68761

**~500K**

✓ IHEEZO





Other In-Office


CPT: Various

Sources: Market Scope 2025, CMS HCPCS/CPT databases, AAO IRIS Registry, published clinical literature. Volumes are estimates and include all settings of care

# IHEEZO Key Metrics and Recent Highlights

**IHEEZO**  
(chloroprocaïne HCl ophthalmic gel)<sup>3</sup>

<p><b>+18%</b> </p> <p><b>Unit demand growth<sup>1</sup></b> Q1 '26 vs Q1 '25</p>	<p><b>+49%</b> </p> <p><b>Growth in new accounts<sup>1</sup></b> Q1 '26 vs Q1 '25</p>	<p><b>85.5%</b> </p> <p><b>Re-order rate<sup>1</sup></b> Q1 '26</p>	<p><b>~82%</b> </p> <p><b>Retina-driven volume<sup>1</sup></b> Share of Q1 '26 units</p>
--	--	--	---



1: Harrow Internal data 2: IQVIA data

### Q1 Highlights

**Net Pricing Improvement**  
Estimated ~20-25% improvement in net pricing takes effect H2 2026

---

**First Available Retina Data Generation**

- Retina-specific data to be presented at ASRS in July to accelerate adoption

**Multi-Unit Packaging**

- 5-unit packaging to be introduced in July 2026

**Expanding Clinical Adoption**

- Increasing utilization among retina specialists and in-office procedures

# Ophthalmic Surgical

TRIESENCE

G-MELT Product Candidate



# TRIESENCE Overview & Recent Highlights



## Q1 '26 Highlights

**+136%** ↑

**Unit Volume Growth**

Q1 '26 vs Q1 '25

**44%** 📊

**Volume from Ocular Surgery**

Q1 '26

**~28%** 👥

**New Accounts Growth**

Q1 '26 vs Q4 '25

**6Qs** ♻️

**Consecutive Growth**

Since re-launch

### Market Expansion: Ocular Inflammation

- TAM = 7+ million annual US surgical cases
- Surgical is driving the majority of new volume; expected to accelerate
- Consistently positive clinical outcomes feedback among physicians

### Demand Accelerating

- +113% YoY growth in March '26 unit demand

### Tripled Sales Organization

- Expanded team driving account growth and further pull-through

### Expanding Label

- Clinical trial underway for cataract surgery and pain

### Next Generation Product in Development

- Pre-filled syringe (PFS) format expected in H2 2028 / H1 2029

### Regulatory

Only FDA-approved preservative-free synthetic corticosteroid for injectable ophthalmic use

### Supply

Stable supply agreement with CMO; next-gen formulation in development (H2 2028 / H1 2029 launch)

### Reimbursement

Product-specific J-Code (J-3300); CMS pass-through status since April 2025 (*all settings of care*); Broad coverage with ~96% covered lives

### IP Protection

Orange Book-listed patents through 2029; next-generation PFS launch targeted pre-expiry

# G-MELT: IV and Opioid-Free Procedural Sedation

Fixed dose non-opioid sublingual tablet combining **3 mg midazolam + 50 mg ketamine**

## WHAT MAKES G-MELT DIFFERENT

**⚡ Zydys® Oral Dissolving Tablet (ODT) Technology**  
Dissolves in seconds under the tongue. Exclusive license from Catalent; Zydys® has supported 35+ FDA-approved products over nearly three decades

**📈 Superior PK Profile**  
Rapid absorption through sublingual mucosa results in rapid, systemic circulation and better bioavailability profile than via GI tract absorption

**✅ Pharmacologic Synergy**  
Midazolam offsets the negative effects of ketamine — delivering effective sedation without IV lines or opioids

**🗨️ Global IP Protection**  
Strong IP estate with several issued patents associated with composition-of-matter and method-of-use claims extending through 2036

## MARKET OPPORTUNITY

**5M+**

Initial target market:  
~5M annual U.S. cataract  
surgeries in 2028

**100M+**

Potential short-duration  
procedures in several  
large markets

Source: Internal development plans; Market Scope cataract surgery forecasts.

## PATH TO LAUNCH

### Regulatory Milestones

**✅ Remaining ancillary studies**  
*Initiated – to be completed by Q4*

**🕒 NDA Submission**  
H1 2027

**🕒 Potential FDA Approval**  
H1 2028

**🕒 Potential Launch**  
H2 2028

# Anti-VEGF Biosimilars

BYOOVIZ  
OPUVIZ



# Retina Expansion: Anti-VEGF Biosimilars

Two FDA-approved ophthalmic biosimilars acquired from Samsung Bioepis — addressing the largest market in Ophthalmology

**Byooviz**<sup>®</sup>  
ranibizumab-nuna

ranibizumab-nuna • 0.05 mL injection

First FDA-approved LUCENTIS<sup>®</sup> biosimilar

INDICATIONS

- ✓ Neovascular (Wet) Age-Related Macular Degeneration
- ✓ Macular Edema following Retinal Vein Occlusion (RVO)
- ✓ Myopic Choroidal Neovascularization (mCNV)

↔ Interchangeability status

🇺🇸 U.S. launch: July 2026

**Opuviz**<sup>™</sup>  
aflibercept-yszy

aflibercept-yszy • 0.05 mL injection

FDA-approved EYLEA<sup>®</sup> biosimilar (Jan 2027 REGN Settlement)

INDICATIONS

- ✓ Neovascular (Wet) Age-Related Macular Degeneration
- ✓ Macular Edema following RVO
- ✓ Diabetic Macular Edema (DME) & Diabetic Retinopathy

↔ Interchangeability status

🇺🇸 U.S. launch: 2027



**Strategic fit** — leverages existing commercial infrastructure with clinical synergy alongside IHEEZO & TRISENCE

Trademarks of Biogen


# Specialty Product Focus

VERKAZIA  
NATACYN  
IOPIDINE

# The Verkazia® Opportunity

VKC is a chronic allergic eye disease — driven by immune dysregulation, across a spectrum (from highly underdiagnosed mild cases to severe and sight-threatening cases), which primarily affects children, but can reach into adulthood

## THE DISEASE SPECTRUM



## Chronic inflammation can progress to corneal damage and vision-threatening complications

**MILD VKC** Underdiagnosed; itching, redness with few Rx options beyond antihistamines; large patient population

**SEVERE VKC** Sight-threatening; corneal damage risk without adequate treatment

**STEROID RISKS** Glaucoma/cataract risks make long-term steroid use untenable in children

## WHY IT MATTERS — THE CLINICAL GAP

**~61%**

of VKC patients are inadequately controlled on antihistamines alone<sup>1</sup>

**0**

FDA-approved steroid-sparing therapy existed before VERKAZIA

**THE GAP:** Antihistamines treat symptoms. Steroids carry long-term risk. **No steroid-sparing immunomodulator has addressed the full VKC population** — leaving a large unmet need across both mild and severe disease

## THE VERKAZIA OPPORTUNITY


- Only steroid-sparing immunomodulator approved for VKC
- Clinically proven: significant corneal improvement, symptom reduction & less steroid rescue vs. control
- Guideline-supported: 2023 consensus recommends early CsA use for long-term management
- Mild (new-to-Rx) and severe (steroid-dependent) patients represent a large, underpenetrated opportunity

1. Ophthalmology, 2024 — Steroids Dominate Treatment of VKC

# The Third Pathogen: the Natacyn® Opportunity

Blepharitis is not a single infection — it is a microbiome imbalance (or dysbiosis) of the eyelid margin, driven by multiple etiologic pathogens<sup>1</sup>

## THE ETIOLOGIC TRIAD



**BACTERIA** Staphylococcus — lipases, toxins, biofilms<sup>5</sup>

**DEMODEX MITES** Mechanical damage, bacterial vectors<sup>6</sup>

**FUNGI** Candida / Malassezia — under-recognized and persistent<sup>7</sup>

## WHY IT MATTERS — THE CLINICAL GAP

**~50%**

of patients fail when only bacteria or mites are treated<sup>8,9</sup>

**~79%**

of chronic cases show fungal elements — a largely untreated burden<sup>10</sup>

**THE GAP:** Antibiotics treat bacteria; Xdemvy® treats mites; There is **no standard therapy that addresses the fungal component** — leaving post-Xdemvy non-responders symptomatic.

## THE NATACYN OPPORTUNITY

- Only FDA-approved ophthalmic antifungal
- Triple-therapy is biologically rational: antibacterial + antiparasitic + antifungal addresses all three pathogens
- Entry point: Xdemvy® non-responders — a large, underpenetrated refractory population
- Data expected in Q4 2026 to support opportunity

References: 1. Blepharitis & microbiome dysbiosis. Frontiers Med 2024 2. American Academy of Ophthalmology. EyeNet 3. Biology Insights. Fungal Size 4. Microscope Master. Bacteria Size and Shape 5. Blepharitis (Staphylococcus, Toxic, Bacterial). StatPearls 2024 6. Demodex review (mechanical damage, bacterial vector). Eye & Contact Lens 2023 7. Distal Mite of Malassezia/Candida in chronic blepharitis. PMID 16249768 8. Demodex blepharitis: ICS study. PMC 1283048 9. Demodex mite-induced or bacterial blepharitis. Health 10. Fungal origin chronic blepharitis (79%). Eye 2015 - PubMed 26293142

46th Annual Growth Stock Conference | June 2026

HARROV

# IOPIDINE® — Reimbursement Unlocks an Underserved Market

The only FDA-approved therapy to prevent procedural IOP spikes

## CLINICAL EVIDENCE



### Indication

Only FDA-approved product to prevent IOP spikes following in-office laser procedures



### ~91% Risk Reduction

Severe IOP spikes drop from ~23% untreated to ~2% with IOPIDINE



### Risks if Unmanaged

Eye pain, blurred vision, and potential optic nerve damage in vulnerable patients

## REIMBURSEMENT INFLECTION

### BEFORE

Historically underutilized — no in-office reimbursement pathway & cost-center for physicians out of capitated fee

### AFTER — JULY 1, 2026

Permanent J-code (J2374) takes effect — physicians can bill for IOPIDINE at point of care and get reimbursed at WAC +3% to 6% (at launch), and eventually ASP +6%

**Key:** Clinical evidence is established. The J-code removes the final barrier to routine adoption

## MARKET OPPORTUNITY

>1.5M\*

Annual U.S. Laser Procedures

~91%

Relative Risk Reduction

J-Code J2374

Effective July 1, 2026

## DRIVERS OF ADOPTION

- ✓ **Ageing population:** Growing procedure volumes; earlier intervention is standard of care
- ✓ **Prevention economics:** Reduces follow-up visits and complication costs
- ✓ **Monopoly indication:** No FDA-approved alternative with an established J-code
- ✓ **Low penetration = upside:** J-code aligns incentives with evidence-based practice

\*Source: CMS Part B laser procedure estimates

46th Annual Growth Stock Conference | June 2026

HARROW

# Summary

# Investment Summary

## Why Invest In Harrow Now

- Proven, market-leading ophthalmic platform
- Highly diversified within ophthalmic care
- U.S. centric
- Largest portfolio of Rx ophthalmic products
- Multiple long-duration growth vectors
- Durable patent protection through late 2030s
- Robust pipeline; near-term potential launches

**41%** 5 Yr Rev CAGR

**62%** 5 Yr EBITDA CAGR

## EARLY-STAGE GROWTH ACROSS ALL KEY REVENUE DRIVERS

Significant untapped market opportunity across all key revenue drivers — with products still early in their adoption curves and positioned to drive substantial long-term revenue and high-margin growth

- 01 Market-Leading Ophthalmic Portfolio**  
Largest diversified portfolio of prescription ophthalmic products in the U.S. — supported by durable IP protection across key revenue drivers through the late 2030s, a scaled commercial infrastructure, and a robust pipeline
- 02 Multiple Early-Stage Growth Drivers With Long Runway Ahead**  
VEVYE, IHEEZO, and TRIESENCE are underpenetrated assets with multiple near-term adoption catalysts:
  - VEVYE gained preferred PBM status (Jan 2024) and doubled its sales force;
  - IHEEZO will benefit starting in Q3 '26 from new 5-unit packaging, 20-25% increase in NPP, and upcoming retina data;
  - TRIESENCE is accelerating growth in ocular inflammation with a recently tripled sales force
- 03 Significant Embedded Operating Leverage**  
Existing commercial infrastructure supports meaningful revenue scale with limited incremental investment — positioning the business for accelerating EBITDA expansion and cash generation
- 04 Durable Near- and Long-Term Growth Profile**  
Accelerating growth across existing products, annual product launches through 2029 driven by recent M&A and late-stage pipeline (BYOOVIZ, OPUVIZ, G-MELT, YOCHIL, TRIESENCE PFS) — all leveraging existing commercial infrastructure — creates multiple long-duration growth vectors through the decade

**\$350M–\$365M**

FY 2026 Revenue Guidance

**\$80M-100M**

FY 2026 EBITDA Guidance

**Goal of \$250M+ Q Revenue**

By the End of 2027

**\$94.6M**

Cash (Mar 31, 2024)




# HARROW®

Your patients. Our purpose.

1A Burton Hills Blvd., Suite 200  
Nashville, Tennessee 37215  
[Harrow.com](http://Harrow.com)

## Mike Biega

*Vice President of Investor  
Relations & Communications*  
[mbiega@harrowinc.com](mailto:mbiega@harrowinc.com)  
Direct: 617-913-8890



Your patients. Our purpose.